This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge
Eli Lilly (LLY) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 12.90% and 6.32%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Exxon Mobil, Oracle, Eli Lilly and Coke
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exxon Mobil, Oracle, Eli Lilly and Coke
The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics
Sanofi (SNY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Sanofi's (SNY) performance when it reports first-quarter results.
Is a Surprise Coming for Lilly (LLY) This Earnings Season?
by Zacks Equity Research
Lilly (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Lilly (LLY) Deliver a Beat in Coronavirus-Hit Q1 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Lilly's (LLY) performance when it reports first-quarter results.
The Zacks Analyst Blog Highlights: Netflix, Silgan, Citrix Systems, Eli Lilly and FirstEnergy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Silgan, Citrix Systems, Eli Lilly and FirstEnergy
Buy 5 Top Health Care Stocks Ahead of Q1 Earnings Results
by Nalak Das
Economic activities came almost to a standstill in March. However, one sector that witnessed heightening activities is health care.
Q1 Earnings Scorecard and Analyst Reports for Exxon, Oracle & Eli Lilly
by Sheraz Mian
In addition to the Q1 earnings scorecard, today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), Oracle (ORCL) and Eli Lilly (LLY).
Will Lower WarnerMedia Margins Hurt AT&T's (T) Q1 Earnings?
by Zacks Equity Research
Investments in HBO Max for its upcoming launch are likely to get reflected in AT&T's (T) bottom line in the first quarter of 2020.
Will Communications Segment Buoy AT&T's (T) Q1 Earnings?
by Zacks Equity Research
Healthy momentum in wireless business on the back of 5G deployments is likely to get reflected in AT&T's (T) first-quarter 2020 earnings.
Ericsson (ERIC) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Ericsson's (ERIC) first-quarter performance is likely to have benefited from momentum in business led by its strategy to increase investments for technology leadership, including 5G.
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly
5 Top Must-Buy Stocks Set to Beat on Q1 Earnings This Week
by Nalak Das
Despite the coronavirus-led economic disaster, five stocks with a favorable Zacks Rank are set to beat Q1 earnings estimates this week.
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
Pharma Stock Roundup: JNJ's Q1 Earnings, Coronavirus Product Development Efforts
by Kinjel Shah
J&J (JNJ) announces Q1 results. Several companies offer update on their studies/plans to make coronavirus treatments or vaccines
Buy 5 Top Medical Stocks on Coronavirus Drug Trial Results
by Nalak Das
The whole world has pinned hopes on pharmaceutical and biotech companies to create drugs and vaccine to help combat COVID-19.
Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vanda Begins Enrollment in Study for Severe Coronavirus Infection
by Zacks Equity Research
Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory lung injury associated with COVID-19 infection.
CytoDyn's Leronlimab Progressing Well in Coronavirus Program
by Zacks Equity Research
CytoDyn (CYDY) treats first patient in a phase IIb/III study evaluating leronlimab in severe and critically ill COVID-19 patients. A phase II study on leronlimab shows encouraging results in mild-to-moderate COVID-19 patients.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $151.18, moving +0.05% from the previous trading session.
Pharma Q1 Earnings Begin With J&J's Report: 3 Stocks to Buy
by Kinjel Shah
Investors typically look at J&J's (JNJ) results for signals about how the rest of the big drugmakers will fare.
AstraZeneca to Begin Calquence Study for Coronavirus Treatment
by Zacks Equity Research
AstraZeneca (AZN) to initiate enrollment in a clinical study to evaluate its blood cancer drug, Calquence, as a potential treatment for patients hospitalized with COVID-19 infection.
Buy 5 Top Stocks Set to Beat on Q1 Earnings This Month
by Nalak Das
Despite the economic disaster, a few stocks are likely to report better-than expected earnings results when they report their financial numbers this month.